10 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18281974 | Inverse thermogelling polyoxazoline copolymers | SERGENT, RABON A | 1765 | Non-Final OA | Sep 14, 2023 |
| 18021387 | MODIFIED LYMPHOCYTES | NICOL, ALEXANDER W | 1634 | Non-Final OA | Feb 14, 2023 |
| 18019238 | SIGLEC-6-BINDING POLYPEPTIDES | JUEDES, AMY E | 1644 | Non-Final OA | Feb 01, 2023 |
| 18145837 | USE OF FLT3 CAR-T CELLS AND FLT3 INHIBITORS TO TREAT ACUTE MYELOID LEUKEMIA | BUTTICE, AUDREY L | 1647 | Final Rejection | Dec 22, 2022 |
| 18058347 | CONTROL AND MODULATION OF THE FUNCTION OF GENE-MODIFIED CHIMERIC ANTIGEN RECEPTOR T CELLS WITH DASATINIB AND OTHER TYROSINE KINASE INHIBITORS | JARRELL, NOBLE E | 1699 | Non-Final OA | Nov 23, 2022 |
| 17910327 | AFFINITY MATURED AND HUMANIZED BINDING DOMAINS TARGETING ROR2 | BRISTOL, LYNN ANNE | 1643 | Final Rejection | Sep 08, 2022 |
| 17819465 | AGENT FOR USE IN THE TREATMENT AND PROPHYLAXIS OF POSTISCHEMIC TISSUE INJURY | HOWARD, ZACHARY C | 1674 | Final Rejection | Aug 12, 2022 |
| 17619569 | ULTRAMODULAR IGG3-BASED SPACER DOMAIN AND MULTI-FUNCTION SITE FOR IMPLEMENTATION IN CHIMERIC ANTIGEN RECEPTOR DESIGN | MIDDLETON, DANAYA L | 1674 | Final Rejection | Dec 15, 2021 |
| 17475189 | ROR1-SPECIFIC CHIMERIC ANTIGEN RECEPTORS (CAR) WITH HUMANIZED TARGETING DOMAINS | NICOL, ALEXANDER W | 1634 | Final Rejection | Sep 14, 2021 |
| 16645072 | PHARMACEUTICALS AND DEVICES FOR THE COVALENT IMMOBILIZATION TO THE EXTRACELLULAR MATRIX BY TRANSGLUTAMINASE | STEADMAN, DAVID J | 1656 | Non-Final OA | Mar 06, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial